Pfizer Highlights Next I&I Star As Xeljanz Sales Fall

The company is looking to refuel its immunology & inflammation portfolio as Xeljanz safety takes a toll and the franchise approaches loss of exclusivity.

stars
Pfizer highlighted etrasimod as a next portfolio star • Source: Shutterstock

Pfizer Inc. has a new near-term commercial opportunity that it hopes will refuel its immunology and inflammation portfolio as the blockbuster rheumatoid arthritis drug Xeljanz (tofacitinib) comes under pressure. Management highlighted etrasimod, which it gained through the acquisition ofArena Pharmaceuticals, Inc., during its first quarter sales and earnings call on 3 May as a drug that could return its I&I portfolio to growth.

Xeljanz, an oral JAK inhibitor, has long been the cornerstone of Pfizer's I&I portfolio, while the company has also sought...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category